Duchenne UK Charity Film

Thank you for watching. For further information please read OUR IMPACT.

We would like to thank all those who helped us to create this film.

Latest

Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

We are excited to share the news with the Duchenne community highlighting an important advancement in the Phase 1b, Multicenter, Open-label, Single Ascending Dose Study.
Soy Products Study: Your Questions Answered

Duchenne UK recently posted a publication by Professor Steve Winder investigating a nutraceutical soy project Haelan 951. Following the publication, Duchenne UK have collated some of the questions from the Duchenne community and working with Steve Winder we have answered them.
VISION-DMD Update:

VISION-DMD is an EC funded project undertaking Phase 2 clinical studies on vamorolone, a new treatment for DMD. Vamorolone (also known as VBP15) is a dissociative steroid designed to have the efficacy of a steroid, without the severe associated side effects. The first Phase 2b study site is expected to open for recruitment in April 2018
An update on soy product research funded by Duchenne UK

In August 2016 Duchenne UK commissioned Professor Steve Winder at The University of Sheffield to investigate a nutraceutical soy product called Haelan 951, as a treatment for Duchenne muscular dystrophy. Results of the study published today in PLOS Currents.